VHAM
PCRX icon

Van Hulzen Asset Management’s Pacira BioSciences PCRX Stock Holding History

Van Hulzen Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-150
Closed -$2.83K – 865
2024
Q4 		$2.83K Sell
150
-71,022
-100% -$1.25M ﹤0.01% 896
2024
Q3 		$1.07M Buy
71,172
+7,006
+11% +$120K 0.08% 155
2024
Q2 		$1.84M Buy
64,166
+29,784
+87% +$848K 0.12% 120
2024
Q1 		$1M Buy
34,382
+447
+1% +$13.7K 0.07% 167
2023
Q4 		$1.15M Buy
33,935
+2,294
+7% +$67.1K 0.08% 144
2023
Q3 		$971K Buy
31,641
+10,664
+51% +$384K 0.07% 150
2023
Q2 		$841K Buy
20,977
+2,283
+12% +$94.4K 0.07% 134
2023
Q1 		$763K Buy
18,694
+4,313
+30% +$172K 0.07% 138
2022
Q4 		$555K Buy
14,381
+852
+6% +$41.5K 0.06% 161
2022
Q3 		$720K Buy
13,529
+702
+5% +$39K 0.09% 140
2022
Q2 		$748K Buy
12,827
+85
+0.7% +$5.57K 0.09% 134
2022
Q1 		$972K Buy
12,742
+178
+1% +$11.9K 0.1% 113
2021
Q4 		$756K Buy
12,564
+5,798
+86% +$320K 0.08% 137
2021
Q3 		$379K Buy
+6,766
New +$390K 0.06% 189

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Van Hulzen Asset Management's PCRX Position: Q1 2025 in Review

Van Hulzen Asset Management sold out of Pacira BioSciences (PCRX) in Q1 2025, closing a stake of 150 shares — an estimated $2.83K sold.

Van Hulzen Asset Management first reported a position in PCRX in Q3 2021 and held it in 14 quarters. The position peaked at $1.84M in Q2 2024. 235 funds tracked by Wall St. Rank hold PCRX as of Q1 2025.

  • Van Hulzen Asset Management reported no remaining Pacira BioSciences position as of Q1 2025 after selling out during the quarter.
  • Van Hulzen Asset Management sold 150 Pacira BioSciences shares in Q1 2025, an estimated $2.83K.
  • Van Hulzen Asset Management first reported a position in Pacira BioSciences in Q3 2021 and held it in 14 quarters.
  • Van Hulzen Asset Management's Pacira BioSciences position peaked at $1.84M in Q2 2024.
  • 235 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2025.

Based on Van Hulzen Asset Management's 13F filing for Q1 2025, filed 14 May 2025.